Stokkel M P, van Eck-Smit B L, Zwinderman A H, Willems L N, Pauwels E K
Department of Diagnostic Radiology and Nuclear Medicine, Leiden University Medical Centre, The Netherlands.
J Cancer Res Clin Oncol. 1998;124(3-4):215-9. doi: 10.1007/s004320050157.
At present the standard staging procedure in patients with small-cell lung cancer (SCLC) is extensive, expensive and time-consuming. Furthermore, the predictive and prognostic value of the current staging system is poor. To determine the value of pretreatment clinical and biochemical parameters to predict tumour stage and to assess prognosis, a retrospective study was performed of 121 consecutive patients with newly diagnosed SCLC.
On the basis of routine diagnostic procedures, 51 patients were staged as having limited disease and 70 patients as having extensive disease. During follow-up, data on tumour progression and survival were gathered. These data and the tumour stage were correlated with lactate dehydrogenase (LDH), alkaline phosphatase, liver enzymes, leucocyte count, protein, albumin, calcium, age and gender.
Follow-up ranged from 1 week to 96 months, during which 110 patients died. In all patients with LDH levels above 400 U/l (n = 31), metastases were found at the initial stage, whereas all patients initially staged as having limited disease and LDH levels above 240 U/l showed tumour progression. Bone and liver were found to be the most commonly involved sites, whereas the incidence of brain metastases increased during follow-up. In patients initially staged as having limited disease, no differences in survival were found between those showing local recurrence and those developing metastases during follow-up (P = 0.67). Compared to the patients initially staged as having extensive disease, the survival of both groups was significantly better (P < 0.001). Significant independent variables of survival were LDH, albumin, initial stage and gender, but LDH was the best overall predictor (P < 0.001).
These results suggest that pretreatment LDH may be used as an additional staging parameter in SCLC, which can identify prognostic subgroups before treatment.
目前,小细胞肺癌(SCLC)患者的标准分期程序繁杂、费用高昂且耗时。此外,当前分期系统的预测和预后价值较差。为了确定治疗前临床和生化参数对预测肿瘤分期及评估预后的价值,对121例新诊断的连续性SCLC患者进行了一项回顾性研究。
根据常规诊断程序,51例患者被分期为疾病局限型,70例患者为疾病广泛型。在随访期间,收集了肿瘤进展和生存数据。这些数据以及肿瘤分期与乳酸脱氢酶(LDH)、碱性磷酸酶、肝酶、白细胞计数、蛋白质、白蛋白、钙、年龄和性别进行了相关性分析。
随访时间为1周至96个月,期间110例患者死亡。在所有LDH水平高于400 U/L的患者(n = 31)中,初始阶段即发现有转移,而所有初始分期为疾病局限型且LDH水平高于240 U/L的患者均出现肿瘤进展。发现骨和肝是最常受累的部位,而脑转移的发生率在随访期间有所增加。在初始分期为疾病局限型的患者中,随访期间出现局部复发和发生转移的患者之间生存率无差异(P = 0.67)。与初始分期为疾病广泛型的患者相比,这两组患者的生存率均显著更高(P < 0.001)。生存的显著独立变量为LDH、白蛋白、初始分期和性别,但LDH是总体最佳预测指标(P < 0.001)。
这些结果表明,治疗前LDH可作为SCLC的一个额外分期参数,能够在治疗前识别预后亚组。